ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
IntReALL HR 2010: International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Protocol ID
IntReALL HR 2010
Condition/s
Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage
Relapse/ refractory
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Charite University, Berlin, Germany
Collaborators
St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria)
European Organisation for Research and Treatment of Cancer - EORTC
University Hospital Motol (Co-Sponsor Czech Republic)
Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark)
Turku University Central Hospital (co-sponsor, Finland)Centre Hospitalier Universitaire de Nice
Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)
Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)
Ospedale Pediatrico Bambino (co-sponsor, Italy)
Prinses Máxima Centrum (Co-Sponsor Netherlands)
Oslo University Hospital (co-sponsor, Norway)
Medical University of Wroclaw (Co-Sponsor Poland)
Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal)
Karolinska University Hospital Stockholm (co-sponsor, Sweden)
Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)
University Children's Hospital Zürich (co-sponsor, Switzerland)
Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)
Trial Status
Completed
Trial Close Date
05/06/2024
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 18 years
International registry ID's
NCT03590171
Back to Registry
Study Title IntReALL HR 2010: International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Protocol ID IntReALL HR 2010
Disease (Sub Disease) Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage Relapse/ refractory
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ Charite University, Berlin, Germany
Collaborators St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria)/ European Organisation for Research and Treatment of Cancer - EORTC/ University Hospital Motol (Co-Sponsor Czech Republic)/ Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark)/ Turku University Central Hospital (co-sponsor, Finland)Centre Hospitalier Universitaire de Nice/ Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)/ Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)/ Ospedale Pediatrico Bambino (co-sponsor, Italy)/ Prinses Máxima Centrum (Co-Sponsor Netherlands)/ Oslo University Hospital (co-sponsor, Norway)/ Medical University of Wroclaw (Co-Sponsor Poland)/ Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal)/ Karolinska University Hospital Stockholm (co-sponsor, Sweden)/ Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)/ University Children's Hospital Zürich (co-sponsor, Switzerland)/ Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)
Links https://clinicaltrials.gov/ct2/show/NCT03590171
Trial Status Completed
Trial Open Date 16/05/2019
Trial Close Date 05/06/2024
Sites The Children's Hospital at Westmead / John Hunter Children's Hospital / Monash Children's Hospital / Sydney Children's Hospital / Women's & Children's Hospital / Christchurch Hospital / Starship Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility up to 18 years
International registry ID's NCT03590171

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168